JPRN-UMIN000001835已完成1 期
Phase1 study of adoptive cell transfer therapy for advanced cancer patients, using stimulated T cells by CH-296. - Adoptive CH-296-stimulated T cells transfer therapy
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine0 个研究点目标入组 9 人开始时间: 2009年4月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Presence of uncontrolled infection 2) Hypersensitivity or autoimmune disease requiring treatments 3) Presence of severe comlications(malignant hypertension, congestive heart failure, severe coronary disease, history of myocardial infarction less than six months prior, pulmonary fibrosis or active interstitial pneumonitis) 4) Inappropriate patients for this study due to severe complications. 5) Active other malignancy, except lesions of "carcinoma in situ" or intramucosal location which are curatively resectable. 6) Medical history of severe hypersensitivity. 7) Severe mental impairment 8) Pregnant or lactating women 9) Inappropriate patients for study judged by the physicians.
研究者
相似试验
已完成
1 期
Phase 1/2 study of adoptive cell therapy using cultured tumor infiltrating lymphocytes with lympho-depleting non-myeloablative preconditioning for patients with advanced melanomaJPRN-UMIN000030143Keio University School of Medicine14
未知
1 期
Phase I/II study of adoptive immunotherapy using cytotoxic T cells specific for minor histocompatibility antigen restricted to hematopoietic cells for patients with high-risk leukemia that relapsed following allogeneic hematopoietic stem cell transplantatio1) RAEB, CMML 2) AML or ALL in induction failure or beyond first remission 3) Ph/p190-positive ALL at any stage 4) imatinib-resistant CMJPRN-C000000162Aichi Cancer Center30
进行中（未招募）
1 期
Development of cell therapy for Salivary gland regeneratioJPRN-jRCTb070190057Asahina Izumi6
进行中（未招募）
1 期
Clinical study with autologous CIK cells for patients with advanced and uresectable sarcomapatients with advanced and non-resectable sarcomaMedDRA version: 20.0Level: PTClassification code 10039491Term: SarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002257-11-ITAOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO35
终止
2 期
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaMelanomaSkin CancerNCT02111863National Cancer Institute (NCI)6